Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10975931rdf:typepubmed:Citationlld:pubmed
pubmed-article:10975931lifeskim:mentionsumls-concept:C0205725lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0014644lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0019381lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0040556lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0221277lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0024282lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C1446409lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C1708067lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C0205344lld:lifeskim
pubmed-article:10975931lifeskim:mentionsumls-concept:C1709707lld:lifeskim
pubmed-article:10975931pubmed:issue9lld:pubmed
pubmed-article:10975931pubmed:dateCreated2000-10-3lld:pubmed
pubmed-article:10975931pubmed:abstractTextTo determine the proportion of patients with evidence of an acute infection due to Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), Toxoplasma, or human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) in heterophile-negative patients with an absolute lymphocytosis or an instrument-generated atypical lymphocyte flag, and to develop a cost-effective testing algorithm for managing such heterophile-negative patients.lld:pubmed
pubmed-article:10975931pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10975931pubmed:languageenglld:pubmed
pubmed-article:10975931pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10975931pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10975931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10975931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10975931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10975931pubmed:statusMEDLINElld:pubmed
pubmed-article:10975931pubmed:monthSeplld:pubmed
pubmed-article:10975931pubmed:issn0003-9985lld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:ThomasEElld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:MathiasRRlld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:BrigdenM LMLlld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:RaboudJJlld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:DoyleP WPWlld:pubmed
pubmed-article:10975931pubmed:authorpubmed-author:TsaparasY FYFlld:pubmed
pubmed-article:10975931pubmed:issnTypePrintlld:pubmed
pubmed-article:10975931pubmed:volume124lld:pubmed
pubmed-article:10975931pubmed:ownerNLMlld:pubmed
pubmed-article:10975931pubmed:authorsCompleteYlld:pubmed
pubmed-article:10975931pubmed:pagination1324-30lld:pubmed
pubmed-article:10975931pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:meshHeadingpubmed-meshheading:10975931...lld:pubmed
pubmed-article:10975931pubmed:year2000lld:pubmed
pubmed-article:10975931pubmed:articleTitleProportion positive for Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, Toxoplasma, and human immunodeficiency virus types 1 and 2 in heterophile-negative patients with an absolute lymphocytosis or an instrument-generated atypical lymphocyte flag.lld:pubmed
pubmed-article:10975931pubmed:affiliationUniversity of Calgary Medical School, Calgary, Alberta, Canada.lld:pubmed
pubmed-article:10975931pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10975931lld:pubmed